Can cardiac iodine-123 metaiodobenzylguanidine imaging contribute to risk stratification in heart failure patients?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 3, 2008, Pages 532-534

  Bax, Jeroen J ^a   Boogers, Mark ^a   Henneman, Maureen M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; BETA ADRENERGIC RECEPTOR; HYDROXYEPHEDRINE C 11; NORADRENALIN; OXYGEN; TRACER;

ADRENERGIC ACTIVITY; ADRENERGIC SYSTEM; CARDIAC PATIENT; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; DRUG UPTAKE; FOLLOW UP; HEART FAILURE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART PERFORMANCE; HEART RATE; HUMAN; LUNG WEDGE PRESSURE; NORADRENALIN BLOOD LEVEL; NOTE; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VENOUS RETURN;

3-IODOBENZYLGUANIDINE; CORONARY ARTERY DISEASE; HEART; HEART FAILURE; HUMANS; PROGNOSIS; RADIOPHARMACEUTICALS; RISK ASSESSMENT; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 43349107101     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-008-0722-4     Document Type: Note

References (19)

1. American Heart Association. Heart disease and stroke statistics, 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85-151.
2. Gheorghiade M, Bonow RO. Chronic heart failure in the United States. A manifestation of coronary artery disease. Circulation. 1998;97:282-9.
3. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397-402.
4. Hartmann F, Ziegler S, Nekolla S, Hadamitzky M, Seyfarth M, Richardt G, et al. Regional patterns of myocardial sympathetic denervation in dilated cardiomyopathy: an analysis using carbon-11 hydroxyephedrine and positron emission tomography. Heart. 1999;81:262-70.
5. Bengel FM, Schwaiger M. Assessment of cardiac sympathetic neuronal function using PET imaging. J Nucl Cardiol. 2004;11:603-16.
6. Bengel FM, Permanetter B, Ungerer M, Nekolla S, Schwaiger M. Relationship between altered sympathetic innervation, oxidative metabolism and contractile function in the cardiomyopathic human heart; a non-invasive study using positron emission tomography. Eur Heart J. 2001;22:1594-600.
7. Pietila M, Malminiemi K, Ukkonen H, Saraste M, Någren K, Lehikoinen P, et al. Reduced myocardial carbon-11 hydroxyephedrine retention is associated with poor prognosis in chronic heart failure. Eur J Nucl Med. 2001;28:373-6.
8. Flotats A, Carrio I. Cardiac neurotransmission SPECT imaging. J Nucl Cardiol. 2004;11:587-602.
9. Carrio I. Cardiac neurotransmission imaging. J Nucl Med. 2001;42:1062-76.
10. Wieland DM, Brown LE, Rogers WL, Worthington KC, Wu JL, Clinthorne NH, et al. Myocardial imaging with a radio-iodinated norepinephrine storage analog. J Nucl Med. 1981;22:22-31.
11. Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med. 1992;33:471-7.
12. Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Randé JL, Duval AM, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med. 1999;40:917-23.
13. Cohen-Solal A, Esanu Y, Logeart D, Pessione F, Dubois C, Dreyfus G, et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol. 1999;33:759-66.
14. Nakata T, Miyamoto K, Doi A, Sasao H, Wakabayashi T, Kobayashi H, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol. 1998;5:579-90.
15. Wakabayashi T, Nakata T, Hashimoto A, Yuda S, Tsuchihashi K, Travin MI, et al. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac events. J Nucl Med. 2001;42:1757-67.
16. Ogita H, Shimonagata T, Fukunami M, Kumagai K, Yamada T, Asano Y, et al. Prognostic significance of cardiac (123)I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study. Heart. 2001;86:656-60.
17. Yamada T, Shimonagata T, Fukunami M, Kumagai K, Ogita H, Hirata A, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: a prospective study. J Am Coll Cardiol. 2003;41:231-8.
18. Anastasiou-Nana MI, Terrovitis JV, Athanasoulis T, Karaloizos L, Geramoutsos A, Pappa L, et al. Prognostic value of iodine-123- metaiodobenzylguanidine myocardial uptake and heart rate variability in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2005;96:427-31.
19. Agostini D, Verberne HJ, Burchert W, Knuuti J, Povinec P, Sambuceti G, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multi-center study. Eur J Nucl Med Mol Imaging. 2007. DOI 10.1007/s00259-007- 0639-3.